Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeeing Machines Regulatory News (SEE)

Share Price Information for Seeing Machines (SEE)

Share Price is delayed by 15 minutes
Get Live Data
4.60    -0.05 (-1.08%)
Bid:
4.55
Ask:
4.615
Spread: 0.065 (1.429%)
Market Cap: £220.78m
SEE Live PriceLast checked at - London Stock Exchange

Intraday Seeing Machines Share Chart

1st Glaucoma Trial Completion

10 Jan 2006 09:18

Seeing Machines Limited10 January 2006 10 January 2006 SEEING MACHINES LIMITED ("Seeing Machines" or "the Company") NON -CONTACT OBJECTIVE GLAUCOMA DEVICE SUCCESSFULLY COMPLETES FIRST MAJOR CLINICAL TRIAL Seeing Machines Limited (AIM : SEE), a leading developer of advanced computerbased imaging software systems, announces the completion of the first majorclinical trial of its new groundbreaking technology for objective detection andmanagement of glaucoma, the group of eye diseases that affect peripheral vision,often leading to permanent loss of vision. Seeing Machines is developing a new medical device that assists clinicians todiagnose and manage disorders of the human visual system, particularly glaucoma. This recent trial has demonstrated with meaningful clinical utility, that thetechnology, as it stands today: • successfully detects the loss of visual field associated withglaucoma, and • successfully differentiates between those patients with visual fieldloss and those without, thus providing the basis for a reliable and accuratediagnostic instrument. Furthermore the trial has demonstrated significant opportunities for greatlyimproving the performance of the technology from the base-line used in thistrial. Commenting on the trial, Nick Cerneaz, Chief Executive of Seeing Machines said: "The technical progress demonstrated in this trial has assisted Seeing Machinesin reaching a key milestone of our entire medical device development program.Our scientific teams, led by Drs. Ted Maddess and Andrew James from theAustralian National University, have done a tremendous job so far and we are nowwell advanced in the development work arising from this trial. The preparationsfor the next major clinical trial aimed at testing these developments are wellunderway with an anticipated start date this quarter. We are very excited aboutthese results and keen to build further on them as we pursue our goal ofdelivering the world's first non-contact objective test for glaucoma." Enquiries:Seeing Machines Limited Insinger de Beaufort Parkgreen CommunicationsNick Cerneaz, CEO Simon Fox Justine Howarth / Victoria Thomas+61 (0) 2 6125 6501 +44 (0) 20 7190 7018 +44 (0) 20 7493 3713www.seeingmachines.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
2nd Jan 201411:29 amRNSHolding(s) in Company
2nd Jan 201410:20 amRNSHolding(s) in Company
30th Dec 20137:46 amRNSResult of EGM
23rd Dec 20137:00 amRNSPosting of Documents
20th Dec 201312:36 pmRNSDirector and Significant Shareholder Dealing
20th Dec 20138:41 amRNSDirector Dealing
16th Dec 20137:00 amRNSSeeing Machines Signs First Cat Dealer Agreement
13th Dec 201311:46 amRNSHolding(s) in Company
10th Dec 20137:00 amRNSRoyal Beuk strategic agreement
5th Dec 20137:00 amRNSNotice of General Meeting
29th Nov 20137:00 amRNSCapital Raising
11th Nov 20137:00 amRNSDSS projects with Freeport-McMoRan
31st Oct 20139:07 amRNSResult of AGM
25th Oct 20131:08 pmRNSDSS trial with Cliffs Natural Resources
26th Sep 201312:00 pmRNSNotice of AGM
24th Sep 20137:00 amRNSHoldings in Company and Director Dealing
17th Sep 20133:54 pmRNSHolding(s) in Company
13th Sep 201310:14 amRNSHolding(s) in Company
9th Sep 20137:00 amRNSAnnual Report and Accounts
5th Sep 201311:30 amRNSImplementation of Long Term Incentive Plan
2nd Sep 20137:00 amRNSDSS Orders Received from BHP Billiton
21st Aug 20137:00 amRNSPreliminary Unaudited Results
25th Jun 20137:00 amRNSTrading Update
18th Jun 20137:00 amRNSAppointment of CFO
28th May 20134:05 pmRNSAlliance with Caterpillar Global Mining
25th Mar 20137:00 amRNSHalf Yearly Report
15th Jan 201310:09 amRNSAppointment of New Director
10th Dec 20128:30 amRNSIssue of Equity
30th Nov 20127:00 amRNSLargest single sale of DSS units
28th Nov 201210:22 amRNSResult of AGM
27th Nov 20127:01 amRNSAGM Statement
27th Nov 20127:00 amRNSChange of Adviser
26th Oct 201211:55 amRNSIssue of Equity to raise £1.272m Replacement
25th Oct 20127:03 amRNSFinal results and Notice of AGM
19th Oct 201212:37 pmRNSIssue of Equity to raise £1.272 million
26th Sep 20127:00 amRNSPreliminary results for year ended 30 June 2012
23rd Aug 201212:45 pmRNSHolding(s) in Company
23rd Aug 201212:45 pmRNSSignificant Shareholder Notification
19th Jul 20129:07 amRNSDistributor Booyco orders a further 50 DSS units
29th Jun 20127:00 amRNSDSS makes inroads in South Africa
25th Jun 20127:35 amRNSDSS Rollout at Cloud Peak Energy
16th Apr 20127:00 amRNSDirectorate Change
29th Mar 20127:00 amRNSHalf Yearly Report
22nd Mar 20127:00 amRNSNotice of Results
3rd Feb 20127:00 amRNSSignificant Shareholder Notification
30th Jan 20127:00 amRNSLaunch of DSS version 3.0
30th Jan 20127:00 amRNSLaunch of Fatigue Consulting Services
18th Jan 20129:30 amRNSCFO Appointment
3rd Jan 20127:00 amRNSDirectorate Changes
14th Dec 20119:38 amRNSResignation of Chairman

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.